| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Nitric oxide (NO) production is the primary target for biological activity. BNN3 itself does not bind to a specific protein; instead, it releases NO which then activates soluble guanylyl cyclase (sGC) leading to cGMP production. NO also interacts with protein thiols to form S‑nitrosothiols.
|
|---|---|
| ln Vitro |
BNN3 produces NO, λEm (max): ~300 nm, using a laser beam or xenon lamp[1].
BNN3 serves as a controlled‑release NO donor; the rate and amount of NO generated in vitro depend on the presence of reducing agents or light activation. In cell‑free systems, BNN3 (10-100 uM) releases NO detected by Griess assay or NO‑specific electrode. This NO production can be inhibited by NO scavengers. |
| ln Vivo |
Due to NO release, BNN3 can produce vasodilation in isolated blood vessels, inhibit platelet aggregation, modulate immune cell activity, and exert cytotoxic effects against tumor cells in vivo. However, specific in vivo dosing and efficacy studies for BNN3 are not well documented in the search results.
|
| Enzyme Assay |
BNN3 is dissolved in DMSO or ethanol. For NO release assays, BNN3 (1-100 microM) is incubated in PBS (pH 7.4) at 37degC. NO concentration is measured using a nitrate/nitrite fluorometric assay kit or an NO electrode. For photolysis experiments, BNN3 is exposed to UV light (350 nm) to trigger NO release; this is useful for time‑controlled studies. No specific receptor binding experiments are applicable.
|
| Cell Assay |
Endothelial cells or smooth muscle cells are seeded in 6‑well plates and treated with BNN3 (1-100 microM). NO production is measured by DAF‑FM DA fluorescent probe. cGMP levels in cell lysates are quantified by ELISA. For functional assays, rat aortic rings are mounted in organ baths, pre‑contracted with phenylephrine, and treated with BNN3 (0.1-100 microM) to measure relaxation. Intracellular calcium levels can be monitored with Fluo‑4 AM.
|
| Animal Protocol |
Animal studies typically involve rodents. BNN3 is administered via intraperitoneal injection (1-10 mg/kg) or intravenous injection. Blood pressure is monitored via carotid artery catheterization to measure vasodilation. In models of septic shock, BNN3 may be given to modulate inflammation. For analgesic studies, BNN3 is injected intrathecally (10-100 microg/rat) and paw withdrawal latency measured. Specific protocols for BNN3 are not detailed in the search results.
|
| ADME/Pharmacokinetics |
Cannot be extracted; information not available. As a small molecule (MW 194.19) that is membrane‑permeant and lipid‑incorporated, BNN3 likely has rapid absorption. It is expected to be metabolically unstable with a short half-life due to rapid conversion to NO. No quantitative PK data (t½, clearance, AUC) is available; most studies focus on local or systemic pharmacodynamic effects.
|
| Toxicity/Toxicokinetics |
BNN3 has not undergone systematic toxicological testing. As an NO donor, potential toxicity may include hypotension (excessive vasodilation), methemoglobinemia from nitrosylation of hemoglobin, and off‑target nitrosative stress causing cellular damage. Short‑term animal studies at moderate doses (mg/kg range) likely have a reasonable safety margin. Carcinogenicity and reproductive toxicity studies are not available.
|
| References |
[1]. Namiki S, et, al. Bis-N-nitroso-caged nitric oxides: photochemistry and biological performance test by rat aorta vasorelaxation. Bioorg Med Chem. 1999 Aug;7(8):1695-702.
|
| Additional Infomation |
BNN3 (N1,N4-Dimethyl-N1,N4-dinitroso-1,4-benzenediamine) is a caged nitric oxide donor used in physiological and pharmacological studies. It is membrane‑permeant and incorporates into lipid bilayers, enabling intracellular NO delivery. It is used to investigate NO signaling in vasodilation, platelet function, and immune response. It may also target the NLRP3 inflammasome, blocking associated signaling pathways. BNN3 is not approved for clinical use. Molecular formula: C8H10N4O2; molecular weight: 194.19.
|
| Molecular Formula |
C8H10N4O2
|
|---|---|
| Molecular Weight |
194.19
|
| Exact Mass |
194.08
|
| CAS # |
6947-38-2
|
| PubChem CID |
245218
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.23g/cm3
|
| Boiling Point |
430.9ºC at 760 mmHg
|
| Flash Point |
214.4ºC
|
| Index of Refraction |
1.58
|
| LogP |
1.921
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
182
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(c1ccc(cc1)N(C)N=O)N=O
|
| InChi Key |
WKDYJAMEXVFEEA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H10N4O2/c1-11(9-13)7-3-5-8(6-4-7)12(2)10-14/h3-6H,1-2H3
|
| Chemical Name |
N-methyl-N-[4-[methyl(nitroso)amino]phenyl]nitrous amide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (257.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1496 mL | 25.7480 mL | 51.4960 mL | |
| 5 mM | 1.0299 mL | 5.1496 mL | 10.2992 mL | |
| 10 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
